

1644

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Tariq Ghayur, *et al.*  
Serial No.: 09/780,035  
Filed: 09 February 2001  
Entitled: ANTIBODIES THAT BIND HUMAN  
INTERLEUKIN-18 AND METHODS OF  
MAKING AND USING



ART UNIT: 1644

EXAMINER: Roark, J.H.

Atty. Docket No.: BBC-084 US

Asst. Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

SEP 03 2002

TECH CENTER 1600/2900

**CERTIFICATE OF MAILING**

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service as First Class Mail under 37 CFR §1.08, postage prepaid, in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

9/25/02 *Angela Perino*  
Date of mailing and signature

*ANGELA PERINO*

**TRANSMITTAL LETTER**

Sir/Madam:

Transmitted herewith are: ☒ An Amendment with photocopy of supporting reference attached as Exhibit A; ☒ A Change of Attorney Docket Number and Change of Correspondence Address (37 CFR 1.8(a)); and ☒ An Acknowledgement Postcard to be filed in the above-identified patent application.

**FEE FOR ADDITIONAL CLAIMS**

- ☒ A fee for additional claims is not required.  
☐ A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEE DUE
TOTAL CLAIMS	38	60	0	× \$18	= 0.00
INDEPENDENT	11	13	0	× \$84	= 0.00
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM				+\$280	= 0.00
TOTAL FEES DUE					= 00.00


**PAYMENT OF ADDITIONAL FEES**

- ☐ The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

**PETITION FOR EXTENSION OF TIME**

- ☐ Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith:
- ☐ \$110.00 for response within first month pursuant to 37 CFR 1.17(a)(1);
  - ☐ \$400.00 for response within second month pursuant to 37 CFR 1.17(a)(2);
  - ☐ \$920.00 for response within third month pursuant to 37 CFR 1.17(a)(3);
  - ☐ \$1,440.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4);
  - ☐ \$1,960.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5);
- ☒ **The Commissioner is hereby authorized to charge payment of any fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 010025. A duplicate copy of this transmittal letter is transmitted herewith.**

Respectfully submitted,



Tara Seshadri  
Agent for Applicants  
Reg. No. 48,591  
Abbott Bioresearch Center, Inc.  
100 Research Drive  
Worcester, MA 01605  
(508) 688-8058

11/B


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ghayur, *et al.*

Serial No.: 09/780,035

Filed: 09 February 2001

Entitled: ANTIBODIES THAT BIND HUMAN  
INTERLEUKIN-18 AND METHODS  
OF MAKING AND USING



ART UNIT: 1644

EXAMINER: Roark, J.H.

Atty. Docket No.: BBC-084 US

Asst. Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

SEP 03 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to the Asst. Commissioner for Patents, Washington, DC 20231, on the date indicated below.

9/25/02 *Angela Perro*  
Date of mailing and signature

*ANGELA PERRO*

AMENDMENT UNDER 37 CFR § 1.111

Sir/Madam:

This paper is filed in response to the Office Action mailed 25 June 2002. This paper is being filed within the three-month shortened statutory period for response. No fee is therefore required.

Please amend the above-captioned application as indicated below:

IN THE CLAIMS

///  
Please cancel claims 1-3, and 13, without waiver or prejudice.

///  
Please amend claims 4, 11, 16 and 46, under the provisions of 37 CFR § 1.121(c)(1)(i) so that they appear as follows:

B1

4. (Amended) A compound comprising a human monoclonal antibody, or antigen-binding portion thereof, capable of binding to human IL-18.